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Lichenoid Tissue Reaction/Interface Dermatitis: Clinical
and Histological Perspectives
Richard D. Sontheimer1
A number of uncommon, clinically diverse and poorly
understood inflammatory skin diseases are linked by
the presence of a set of histopathological elements
that have traditionally been referred to as the
‘‘lichenoid tissue reaction/interface dermatitis’’ (LTR/
IFD). The prototypic skin disease in this category is
lichen planus. However, the LTR/IFD can also be seen
in skin disorders associated with systemic illnesses
(lupus erythematosus, dermatomyositis), and the skin
changes of potentially fatal disorders such as graft-
versus-host disease, Stevens–Johnson syndrome, and
toxic epidermal necrolysis. It has been traditionally
felt that cytotoxic T-lymphocytes represent the final
effector cell type for the epidermal basal cell layer
injury pattern that is common to LTR/IFD disorders.
Recent work has suggested that a number of different
LTR/IFD skin disorders share a common inflammatory
signaling pathway involving the actions of plasmacy-
toid dendritic cell-derived IFN-a. This signaling path-
way appears to amplify cytotoxic T cell injury to the
epidermal basal cell compartment. This review will
summarize the work implicating this pathway as well
as the other cellular and molecular mechanisms that
are thought to be responsible for the prototypic LTR/
IFD disorder, lichen planus. It is hoped that a better
understanding of the immunological commonalities
shared by various LTR/IFD disorders will lead to
more effective safer treatment options for these
illnesses.
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INTRODUCTION
The programmatic theme for the 2007 Montagna Symposium
on the Biology of Skin was ‘‘Keratinocyte-T Cell Interac-
tions’’. Jan P. Dutz, MD, chaired the symposium session that
was entitled ‘‘Lichenoid Tissue Reaction’’. This article
represents a summary of the introductory presentation given
by the author at that session.
Recent work has suggested that a number of different
lichenoid tissue reaction/interface dermatitis (LTR/IFD) clin-
ical disorders may share a common immunopathogenesis
involving plasmacytoid dendritic cell-mediated type I inter-
feron signaling (Blomberg et al., 2001; Farkas et al., 2001;
Meller et al., 2005; Wenzel et al., 2005a, b, c, 2006a, b;
Scheler et al., 2007). The program for the LTR/IFD session of
the 2007 Montagna Symposium was designed to further
explore the hypothesis that certain immunological effector
mechanisms might be common to a variety of clinical
disorders that share elements of the LTR/IFD. In their elegant
discussion of immunological command and control in the
skin, Schroder et al. (2006) voiced a supporting sentiment for
this hypothesis: ‘‘y the lichenoid reaction pattern, which is
seen in such different conditions as drug reactions, skin
manifestations of collagen vascular diseases, chronic cuta-
neous graft-versus-host disease and lichen planus predict a
cutaneous immune program from a provoking stimulus.’’
Exploration of this hypothesis might result in the development
of new, safer therapeutic approaches for this debilitating,
disabling, and sometimes-fatal group of skin disorders. It was
the Montagna Symposium program co-chairs’ hope that a
session focused on the LTR/IFD might lead to new
approaches to better understand and treat this diverse group
of cutaneous disorders.
This article will review the body of knowledge relating to
the etiopathogenesis of the prototypic LTR/IFD disorder,
lichen planus, up until several years ago when the hypothesis
that plasmacytoid dendritic cell production of IFN-a is a
driving force in the LTR/IFD was put forward.
DEFINITIONS, NOMENCLATURE, AND CLASSIFICATION
A number of clinically diverse, poorly understood, and
relatively uncommon inflammatory skin diseases are linked
together by the presence of a pattern of common histopatho-
logical elements that traditionally has been referred to
as the ‘‘lichenoid tissue reaction’’ (LTR) (Pinkus, 1973). These
elements include a pattern of epidermal basal cell morpho-
logical change that has been variously described as being
‘‘liquefactive/hydropic/vacuolar’’ (Figure 1). In the LTR,
this characteristic pattern of epidermal basal cell injury/
REVIEW
1088 Journal of Investigative Dermatology (2009), Volume 129 & 2009 The Society for Investigative Dermatology
Received 8 February 2008; revised 27 March 2008; accepted 14 April 2008;
published online 26 February 2009
1Department of Dermatology, Richard and Adeline Fleischaker Chair in
Dermatology Research, University of Oklahoma Health Sciences Center,
Adjunct Investigator, Oklahoma Medical Research Foundation, Oklahoma
City, Oklahoma, USA
Correspondence: Dr Richard D. Sontheimer, Department of Dermatology,
University of Oklahoma Health Sciences Center, 619 NE, 13th Street,
Oklahoma City, Oklahoma 73104, USA.
E-mail: richard-sontheimer@ouhsc.edu
Abbreviations: APC, antigen-presenting cell; LE, lupus erythematosus;
LTR/IFD, lichenoid tissue reaction/interface dermatitis; MHC, major
histocompatibility complex; TNF, tumor necrosis factor
degeneration is intimately associated with a band-like array
of mononuclear inflammatory cells in the papillary and mid-
dermis consisting of activated T cells, macrophages, and
dendritic cells (Figure 1). Prototypic skin diseases in this
category are lichen planus and cutaneous lupus erythemato-
sus (LE), which are illustrated in Figures 2 and 3.
Lichenoid tissue reaction/interface dermatitis skin
diseases have traditionally been subdivided into those
clinical disorders that display a high-density (‘‘cell-rich’’)
inflammatory infiltrate and those that display a low-density
(‘‘cell-poor’’) infiltrate (Romero et al., 1977; Sontheimer and
Gilliam, 1981). Clinical examples of a cell-rich LTR include
lichen planus and its variants, lichenoid drug reactions,
lichen nitidus, lichen striatus, and some forms of autoimmune
connective tissue skin disease such as discoid LE. Examples of
a cell-poor LTR/IFD include virus- and drug-induced morbilli-
form exanthems, other forms of autoimmune connective
tissue skin diseases (acute cutaneous LE, subacute cutaneous
LE, cutaneous dermatomyositis), acute graft-versus-host skin
disease, and erythema multiforme.
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Figure 1. Histopathology of LTR/IFD. (a) Histopathology of normal human
skin compared with a cell-rich LTR/IFD disorder, (b) lichen planus, and
cell-poor LTR/IFD disorder, (c) subacute cutaneous lupus erythematosus.
Bars¼ 25 mm.
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Figure 2. Examples of clinical varieties of a cell-rich LTR/IFD disorder, lichen planus. (a–c) Most common clinical form of cutaneous lichen planus, lichen
planus rubra. Note the fine basket weave pattern of scale in the image in panel c. This characteristic change is referred to as Wickham’s striae. Panel d illustrates
the linear white network on the buccal mucosa that is characteristic of oral lichen planus. Panel e illustrates erosive lichen planus of the vaginal orifice
with the characteristic associated debilitating scarring.
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Figure 3. Examples of clinical varieties of cell-poor LTR/IFD clinical
disorders. (a) Acute cutaneous LE. Note in the characteristic symmetrical
erythema and scale over the malar eminences. (b) Annular/polycyclic type of
subacute cutaneous LE. (c) Cutaneous dermatomyositis. Note the violaceous
scaling erythema over the posterior aspect of the neck that extended to the
posterior shoulders (the shawl sign). (d) Cutaneous dermatomyositis. Note the
violaceous erythema preferentially targeting the skin over the knuckles.
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More modern workers have begun to refer to this
histological pattern as an ‘‘interface dermatitis’’ (IFD) rather
than as an LTR (Hurwitz et al., 1982; Fitzpatrick 1992;
Crowson and Magro 1997). Some modern workers have
defined ‘‘interface dermatitis’’ more broadly—‘‘The term
interface dermatitis refers to the finding in a skin biopsy of an
inflammatory infiltrate that abuts or obscures the dermal
epidermal junction’’ (Crowson et al., 2008). These workers
feel that the term ‘‘LTR’’ should be reserved for the cell-rich
subset of IFD diseases such as lichen planus (that is, the
designation ‘‘lichenoid’’) (see Figure 1b). However, the
designation ‘‘LTR’’ for this group of diseases remains in use
(Teraki and Shiohara 2004; Tilly et al., 2004; DeRossi and
Ciarrocca 2005; Shiohara and Mizukawa 2005). There were
107 publications in the PubMed database under the search
term ‘‘lichenoid tissue reaction’’ as of October 24, 2007,
whereas there were 1,440 publications listed under the rather
unique search term ‘‘lichenoid’’. There were 195 PubMed
publications under the search term ‘‘interface dermatitis’’.
Thus, to be as inclusive as possible, the terms LTR and IFD
will be used synonymously in this review and referred to
under the designation ‘‘LTR/IFD’’.
EXAMPLES OF CLINICALLY SEVERE LTR/IFD SKIN
DISEASES
The cell-rich and cell-poor LTR/IFD diseases are a diverse
group of clinical disorders. Table 1 presents a comprehensive
listing of such disorders. This list was compiled from several
recent reviews of this subject (Shiohara and Kano, 2003;
Crowson et al., 2008). With respect to clinical diversity, some
of these disorders represent fulminant, potentially fatal
mucocutaneous illnesses (for example, erythema multiforme
major (synonym: Stevens–Johnson syndrome)). Others are
associated with potentially fatal patterns of systemic auto-
immunity (for example, lupus-specific skin diseases, cuta-
neous dermatomyositis). Some represent highly symptomatic
and potentially disfiguring and/or disabling dermatoses (for
example, erosive lichen planus). And still others represent
banal self-limited dermatoses (for example, lichen nitidus,
lichen striatus). Table 2 provides a categorization of tradi-
tional LTR/IFD diseases on the basis of clinical severity and
association with systemic involvement.
Figure 2 presents clinical photos of various clinical
subtypes of lichen planus. Representative cell-poor LTR/IFD
skin disorders are illustrated in Figure 3.
UNCONVENTIONAL LTR/IFD CUTANEOUS DISORDERS
There are other inflammatory skin diseases that display subtle
elements of the LTR/IFD that are not conventionally classified
in the LTR/IFD category. A case can be made that erythema
dyschromicum perstans (ashy dermatosis), vitiligo, alopecia
areata, lichen sclerosis atrophicus, and morphea could also
be considered to be LTR/IFD clinical disorders as they can
manifest subtle features of a ‘‘cell-sparse’’ LTR/IFD. In
addition, an LTR/IFD might serve a protective function in
being responsible for the involution of certain self-resolving
cutaneous proliferative disorders (for example, lichenoid
actinic keratosis, halo nevus, keratoacanthoma).
EPIDEMIOLOGY OF LTR/IFD DISEASES
The epidemiology of many LTR/IFD skin disorders has not
been systematically examined. A number of such disorders
are quite rare, making population-based epidemiological
studies very difficult to perform. Table 3 presents a listing of
environmental agents that have been implicated as triggers
for lichen planus or lichenoid drug eruptions.
ETIOPATHOGENESIS OF LTR/IFD
The abstract of a recent authorative review of the immuno-
logical basis of the LTR/IFD begins with the following
sentence: ‘‘An autoimmune attack by T cells on the epidermis
is the primary pathological event in the lichenoid tissue
reaction’’ (Shiohara and Mizukawa, 2005). It has been
traditionally felt that cytotoxic T-lymphocytes represent the
major effector cell type for the epidermal basal cell layer
injury pattern that is common to LTR/IF disorders. These
conclusions are based primarily upon the histopathological
findings of human LTR/IFD diseases and experimental studies
Table 1. Classification of LTR/IFD skin disorders listed
alphabetically within subgroups
Lymphocyte-rich LTR/IFD
Autoimmune connective tissue diseases
Discoid lupus erythematosus (LE)
Fixed drug eruption
Keratosis lichenoides chronica
Lichen nitidus
Lichen planus
Lichen striatus
Lichenoid drug reactions
Lichenoid and granulomatous dermatitis
Lichenoid graft-versus-host disease
Lichenoid mycosis fungoides
Lymphocyte-poor LTR/IFD
Acute graft-versus-host skin disease
Autoimmune connective tissue skin diseases
LE
Acute cutaneous LE
Subacute cutaneous LE
Dermatomyositis
Mixed connective tissue disease
Erythema multiforme
Erythema multiforme minor
Erythema multiform major (synonym: Stevens–Johnson syndrome)
Interface dermatitis of HIV infection
Morbilliform exanthems
Virus-induced
Drug-induced
Paraneoplastic pemphigus
Pityriasis lichenoides
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in animal models (animal models of LTR/IFD will be
addressed separately in these symposium proceedings by
Dr Jan Dutz).
In some LTR disorders, the antigen being targeted by
activated T cells is known (for example, alloantigens in graft-
versus-host skin disease). In others, the targeted antigen is
thought to be an autoantigen (for example, Ro/SSA and La/SS-
B in neonatal LE and subacute cutaneous LE). However, in
most LTR/IFD disorders, the targeted antigen is unknown,
with cross-reactivity between environmental antigens (for
example, viral, drug, chemical) and self-antigens being
suspected. A number of infectious agents, drugs, and other
chemicals have been implicated as environmental triggers for
lichen planus and lichenoid drug eruptions (Table 3).
For lichen planus, separate research data sets exist for
the oral (Sugerman et al., 2002; Lodi et al., 2005) and
cutaneous (Shiohara and Mizukawa, 2005) manifestations
of this disease. Recent progress in understanding the
cellular immunopathogenesis of oral lichen planus has been
especially notable (Sugerman et al., 2002; Lodi et al., 2005;
Bascones-Ilundain et al., 2006, 2007; Bai et al., 2007;
Gustafson et al., 2007). It is generally felt that the
etiopathogenetic mechanisms of tissue-injury in the oral
mucosal and skin compartments are fundamentally the same
except for the differences that might be predicted on the basis
of differences in anatomical location and environmental
exposure.
It is beyond the scope of this presentation to review all of
the previous work that has been done to unravel the
etiopathogenesis of even the major human LTR/IFD skin
disorders listed in Tables 1 and 2. Therefore, the focus here
will be on lichen planus, the prototypic LTR/IFD clinical
disorder. Even this is a rather broad subject. For more in-
depth discussion of the primary observations relating to the
etiopathogenesis of lichen planus, the reader is referred to
other more in-depth treatments of this subject (Pinkus 1973;
Sontheimer and Gilliam 1981; Shiohara et al., 1986, 1987,
1988a, b, c, 1992; Oliver et al., 1989; Bleicher et al., 1990;
Bratel et al., 1998; Sugerman et al., 2002; Lodi et al., 2005;
Shiohara and Mizukawa, 2005). This review will address
some of the modern currents of thought in this area.
Table 2. A classification of traditional LTR/IFD skin
diseases according to clinical severity and quality-of-
life impact
Minimally-symptomatic, self-limited dermatoses
Lichenoid actinic keratosis
Lichen planus group
Lichen nitidis
Lichen striatus
Significantly symptomatic but self-limited dermatoses
Fixed drug eruption
Lichen planus group
Lichen planus rubra
Severely symptomatic, potentially disfiguring/disabling, difficult-to-treat
dermatoses
Lichen planus group
Erosive lichen planus (synonyms: orovaginalvulvar lichen planus;
vulvovaginal-gingival syndrome)
Dermatoses associated with potentially disabling or life-threatening
systemic diseases
Acute graft-versus-host disease
Dermatomyositis
LE-specific skin diseases
ACLE
SCLE
Discoid LE
Paraneoplastic pemphigus
Life-threatening dermatoses
Erythema multiforme major (synonym: Stevens–Johnson syndrome)
Toxic epidermal necrolysis
Table 3. Some environmental antigens implicated to
be triggering factors in the etiopathogenesis of the
lichen planus or lichenoid drug reactions1
Contactants
Dental amalgams
Mercury
Copper
Gold
Color photography, developing chemicals
Ingestants
Drugs2
Angiotensin-converting enzyme inhibitors
Antimalarials
Calcium channel blockers
Gold
Nonsteroidal anti-inflammatory drugs
Injections
Hepatitis B vaccines
Infections
Hepatitis B
Hepatitis C
Human herpes virus-7
1Data in this table are compiled from the works by Shiohara and Kano
(2003) and Litt (2004).
2The third edition of Jerome Litt’s Pocketbook of Drug Eruptions and
Interactions lists a total of 114 individual drugs that have been implicated
as triggers for lichen planus or lichenoid drug eruptions (Litt, 2004). Listed
above are some of the more common drug classes that can induce a
lichenoid drug eruption.
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Epidermal basal layer target cells
One approach to considering the etiopathogenetic elements
of LTR/IFD is to divide this reaction pattern into its two major
component compartments. The compartment that is the focus
of injury is the epidermal basal cell layer. The compartment
that most authorities feel is responsible for this injury pattern
is the dermal mononuclear cell inflammatory infiltrate.
Whereas other epidermal compartment histological
changes are regularly seen in LTR/IFD disorders such as
lichen planus (for example, orthokeratotic hyperkeratosis,
focal hypergranulosis, irregular acanthosis), the hallmark
epidermal change is damage to and disarray of the cells that
comprise the epidermal basal layer (Figures 1 and 4). In 1973,
Pinkus (1973) stated, ‘‘Lichenoid tissue reaction is defined as
one exhibiting epidermal basal cell damage and the chain of
histobiological events resulting from such damage. It is not
essential whether damage to the basal cells is primary or is
itself due to a preceding event in the dermis. The cascade of
events resulting from damage to the germinal basal cells is
predictable from a general knowledge of epidermal biology.’’
Keratinocyte necrosis in the LTR/IFD disorders. Epidermal
basal cell degeneration seen in the LTR/IFD has been
variously described morphologically with the following
synonymous qualifying terms: hydropic, liquefactive/lique-
faction, vacuolar. These descriptive terms correspond to
Virchow’s basic concept of ‘‘cloudy swelling’’. Cloudy
swelling is a phenomenon that results from rapid cytoplasmic
swelling (oncosis). Oncosis leads to plasma membrane
rupture and organelle breakdown typical of cell necrosis
(Krysko et al., 2008) Cellular necrosis can be induced in
human epidermal cells as well as other cell types by a number
of mechanisms, most prominent being injury by toxins and
oxidative stress. More recently, it has been suggested that
different cellular stimuli including cytokines, ribonucleotides,
ATP depletion, and ischemia can induce cellular necrosis that
follows a sequential process that is suggestive of a cell death
program (Vanden Berghe et al., 2007).
Whereas there are many markers for cellular apoptosis,
there are virtually no positive markers for cellular necrosis.
Traditionally, necrosis has been characterized predominantly
in negative terms by the absence of markers of apoptosis.
However, it has recently been suggested that it might be
possible to actively distinguish apoptosis from necrosis using
a combination of analytical techniques (Krysko et al., 2008).
To the author’s knowledge, this approach has not previously
been applied to any LTR/IFD disorder.
It has traditionally been assumed that the primary
epidermal basal cell layer target in the LTR/IFD is the basal
keratinocyte. As keratinocytes constitute more than 90% of
the epidermal basal layer, the extensive pattern of epidermal
basal layer damage seen in some LTR/IFD disorders such as
lichen planus demands that basaloid keratinocytes be
involved. However, other cell types residing in the basal
layer such as the melanocyte might also be targeted (Figure 4).
In some LTR/IFD skin diseases such as a discoid LE, a
permanent vitiligo-like leukoderma can be seen to occur in
the central inactive areas of lesions.
A role for the Merkel cell as a target of the LTR/IFD has not
been addressed. Whether epidermal basal layer stem cells
might be preferentially targeted in the LTR/IFD has also not
been addressed. The bodies of epidermal Langerhans cells
reside in a suprabasilar position; however, their dendrites
extend into the epidermal basal layer. Interestingly, Langer-
hans cells have been confirmed to be increased in number in
some LTR/IFD skin lesions such as lichen planus (Santoro
et al., 2005) and decreased in others such as cutaneous LE
(Sontheimer and Bergstresser 1982).
Keratinocyte apoptosis in LTR/IFD disorders. Because of the
prominent cloudy swelling changes noted in epidermal basal
cells in various LTR/IFD disorders, previous workers assumed
that the LTR/IFD-associated immune effector cells were
inducing necrotic degeneration of epidermal basal cells.
However, with the growth in understanding of the process of
programmed cell death (apoptosis), it is now recognized that
some epidermal basal cells in a number of LTR/IFD disorders
are also undergoing apoptotic death (for example, lichen
planus, cutaneous LE, cutaneous dermatomyositis, acute and
lichenoid graft-versus-host skin disease). However, it is clear
that the epidermal basal layer damage in LTR is not the sole
result of primary apoptosis (Bascones-Ilundain et al., 2007).
Markers of apoptosis are associated with terminal kerati-
nocyte differentiation. It has been stated that terminal
keratinocyte differentiation seems to be a special form of
apoptosis (Boehm, 2006). However, there are both human
in vivo and in vitro studies that suggest that epidermal
Figure 4. The epidermal basal layer of normal human skin. This is a 1-mm-
thick section of Epon-embedded normal human skin stained with methylene
blue-Azure II-Basic fuchsin. As can be seen, the epidermal basal layer is
morphologically diverse (broken line rectangles). It contains epidermal stem
cells that are differentiating into daughter transient amplifying cells that
subsequently differentiate into basal keratinocytes. It is possible that
epidermal stem cells, transient amplifying cells, and basal keratinocytes could
display varying surface autoantigens that could be targeted by LTR/IFD
effector cells. In addition, the epidermal basal layer contains melanocytes
and, in some anatomical skin regions, Merkel cells. Both of these cell types
have been assumed to be innocent bystanders in the LTR/IFD. Dendrites from
suprabasal epidermal Langerhans cells are intermixed with the cellular
components of the epidermal basal layer. The constituent cell types of normal
human dermis are surrounded by the solid line figure. These cells include
dermal microvascular endothelial cells, pericytes, dendritic cells,
macrophages, mast cells, and fibroblasts. Bar¼25 mm.
1092 Journal of Investigative Dermatology (2009), Volume 129
RD Sontheimer
LTR/IFD
keratinocytes have active defense mechanisms to retard
conventional UVB-induced and cytokine-induced apoptosis.
It has been reported that only a minority of keratinocytes in
suprabasal and mid-epidermal layers of intact human skin
undergo apoptosis after exposure to two minimal erythema
doses of UV radiation (Norris et al., 1997). Epidermal basal
cells were completely resistant to apoptosis. In addition, this
study demonstrated that primary and secondary cultures of
human epidermal keratinocytes as well as epidermal
keratinocyte lines were relatively resistant to UVB-induced
apoptosis and cytokine-induced apoptosis compared with
many other cell types.
It has recently been suggested that expression of anti-
apoptotic molecules in oral lichen planus might counteract the
pro-apoptotic assault and rescue the epithelium from rampant
cell death and resulting clinical ulceration (Karatsaidis et al.,
2007). In this study, biopsies from active lichen planus oral
mucosal lesions and healthy control oral mucosal epithelium
were examined by immunohistochemistry for both pro-and
anti-apoptotic molecules. Both the pro-apoptotic Fas-asso-
ciated death domain protein and the antiapoptotic molecules
I kappa B kinase (p-IKK), NF-kB/p50, FLICE inhibitory protein
(L), inhibitor of apoptosis (cIAP-1) and cIAP-2 markers were
strongly upregulated in lichen planus lesional biopsies
compared with normal oral mucosal biopsies. However, there
were no significant differences in the staining patterns for
active caspase-3 and caspase-8.
In addressing basal cell abnormalities in a recent
authoritative review on oral lichen planus, emphasis was
placed almost entirely on apoptosis as a causative mechan-
ism (Lodi et al., 2005). However, the primary morphological
changes seen in the epidermal basal layer is one of necrosis-
associated cloudy swelling. Future studies need to more
systematically address the relationship between basal cell
apoptosis and necrosis as a basis for clinical differences in
LTR/IFD skin diseases. This will become possible as
molecular tools become available to discriminate between
apoptotic and necrotic pathways of cell death.
Dermal mononuclear inflammatory cells
There are two cell types found in the dermis of lichen planus
lesions that relate directly to the epidermal basal layer
injury—melanophages and colloid bodies (synonyms: hya-
line, cytoid, or Civatte bodies). Melanophages are dermal
phagocytic cells of the macrophage lineage that have
engulfed large amounts of melanin pigment released from
epidermal basal layer keratinocytes and melanocytes that
have been damaged by the LTR/IFD. Colloid bodies are
thought to represent injured basal layer keratinocytes that
have undergone amyloid degeneration.
The dermal mononuclear cell inflammatory infiltrate
holds the most interest with respect to inciting injury in the
epidermal compartment. There are three major bone marrow-
derived inflammatory cell types in the LTR/IFD: T lympho-
cytes, macrophages, dendritic cells.
T cells. The vast majority of lymphoid cells infiltrating the
epidermis and dermis in both oral and cutaneous lichen
planus are T cells. Infiltrating T cells in lichen planus
demonstrate a mixed phenotype of activated CD4/CD8 cells.
There is an enrichment of CD45RO memory T cells that
display a Th1 cytokine bias. IL-17 and IL-23 have recently
emerged as key proinflammatory cytokines in psoriasis
(Zheng et al., 2007). Studies of IL-17 and IL-23 expression
in lichen planus skin lesions have yet to be reported.
However, it has been suggested that an LTR/IFD-related
disorder, graft-versus-host disease, cannot be induced with
T cells from IL-17-deficient animals (Nakae et al., 2002).
In the majority of studies, CD8 T cells have outnumbered
CD4 T cells in both oral and cutaneous lichen planus
lesions (Sugerman et al., 2002; Lodi et al., 2005). HLA class
I-restricted cytotoxic T cell lines and clones have been
isolated from lichen planus lesions. In addition, restricted
T cell receptor V-beta gene expression, especially V-beta 22
and V-beta 23, have been observed in T cells infiltrating oral
lichen planus lesions, suggesting in situ antigen-specific
oligoclonal T cell expansion (Lodi et al., 2005). Perforin- and
granzyme-expressing CD8 T cells have been suggested to
play a primary role in keratinocyte apoptosis in both oral and
cutaneous lichen planus (Shimizu et al., 1997; Kastelan et al.,
2004; Prpic et al., 2004; Santoro et al., 2004).
Recent work has suggested that IFN-a is produced by an
expanded plasmacytoid dendritic cell population in lichen
planus skin lesions (Wenzel et al., 2006a) and in other LTR/
IDs. IFN-a then supports the local production of chemokines
including IP10/CXCL10 by resident cells such as epidermal
keratinocytes. These chemokines recruit CXCR3 chemokine
receptor-expressing cytotoxic T cells into the inflammatory
milleu of lichen planus (Wenzel et al., 2006a, b; Scheler
et al., 2007). These issues will be addressed in greater depth
in other reports to be presented in these symposium
proceedings.
Systematic studies of CD4þ CD25þ regulatory T cells
have yet to be reported in lichen planus. The frequencies of
FOXP3(þ ) and GITR(þ ) (glucocorticoid-induced tumour
necrosis factor receptor) regulatory CD4(þ ) CD25(þ ) T cells
were similar in spongiotic dermatitis, psoriasis, and lichen
planus in one report (de Boer et al., 2007). Another group
reported an enrichment of CD45RO, CD2, and CD25 T cells
in the dermal infiltrate of lichen planus compared with
psoriasis and atopic dermatitis (Bovenschen et al., 2005). As
the methodology to identify and functionally study these cells
improves, their role in the pathogenesis of LTR/ID may need
to be reexamined.
Macrophages. CD68(þ ) macrophages are minor component
of the mononuclear cell infiltrate of lichen planus. The
number and distribution of macrophages in lichen planus
does not appear to differ significantly from that seen in other
inflammatory skin diseases such as psoriasis and various
causes of spongiotic dermatitis (Deguchi et al., 2002).
Dendritic cells. In addition to expanded numbers in the
epidermis, epidermal Langerhans cells have been observed
to be present in the dermal inflammatory infiltrate of
lichen planus lesions. As discussed previously, CD123(þ )
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BDCA-2(þ ) plasmacytoid dendritic cells are expanded
within the inflammatory infiltrate of lichen planus. It has
recently been suggested that plasmacytoid dendritic cells
might be differentially distributed within the inflammatory
infiltrates of two other LTR/IFD skin diseases, cutaneous
dermatomyositis and cutaneous LE (Mcniff and Kaplan,
2007). CD11c(þ )S100(þ )CD68() myeloid dendritic cells,
DC-SIGN(þ ) dendritic cells, and langerin(þ ) epidermal
Langerhans cells have also been reported to be expanded in
the dermal and epidermal compartments of both oral and
cutaneous lichen planus lesions (Santoro et al., 2005; Scheler
et al., 2007).
NK cells. Recent work has implicated CD94(þ ) CD3()
CD56(low) CD16(þ ) ChemR23(þ ) natural killer cells as an
effector cell type in oral lichen planus lesions (Parolini et al.,
2007).
Mast cells. Increased mast cell densities have been observed
in oral lichen planus (Sugerman et al., 2002; Lodi et al.,
2005). A significant percentage of such mast cells were found
to be degranulated. It has been suggested that the pro-
inflammatory milieu associated with degranulated mast cells
might play a role in helping T cells breach the epidermal
basement membrane in lichen planus lesions. In addition,
mast cells are known to be responsive to TLR ligands.
Cells that are typically not present in the LTR/IFD
inflammatory-cell infiltrate. Inflammatory cells that are
typically absent in lichen planus include neutrophils and
eosinophils. However, it cannot be excluded that neutrophils
are not involved in the earliest phases of lichen planus
inflammation as is the case in tuberculin-induced delayed
hypersensitivity reactions. The absence of eosinophils implies
dominance of Th1 cytokine pattern in lichen planus.
Cellular dynamics and interactions. As Lodi et al. (2005)
have pointed out, the majority of T cells within the epithelium
and adjacent to damaged basal keratinocytes in oral lichen
planus are activated CD8 T cells, and CD8 T cells colocalize
with apoptotic keratinocytes. T cell lines and clones that can
be isolated from oral lichen planus lesions are more cytotoxic
against autologous lesional keratinocytes than T cell lines and
clones isolated from clinically normal skin of lichen planus
patients. These data suggest that CD8 lesional T cells may in
part be activated by an antigen associated with major
histocompatibility complex (MHC) class I on basal keratino-
cytes and that activated CD8 cytotoxic T cells may trigger
keratinocyte apoptosis in oral lichen planus. The nature of the
antigen and the key antigen-presenting cell(s) is uncertain in
lichen planus.
Unifying hypotheses relating to the immunopathogenesis
of lichen planus
Tetsuo Shiohara at Kyorin University School of Medicine in
Tokyo, Japan, has maintained a career-long interest in the
immunopathogenesis of LTR/IFD disorders. On the basis of
his own work with experimental animal models of the LTR
as well as observations relating to the human fixed drug
eruption, Shiohara has proposed a unifying hypothesis
concerning the immunopathogenesis of the LTR/IFD (Shio-
hara and Kano, 2003; Shiohara and Mizukawa, 2005).
Shiohara’s work with murine models of the LTR was reviewed
by Dr Jan Dutz at the Montagna ‘‘Lichenoid Tissue Reaction’’
session and will be presented elsewhere in these proceedings.
I will focus here on the model devised by Shiohara et al., to
explain the behavior of memory CD8 T cells in the human
fixed drug eruption as a paradigm for the LTR/IFD in general.
A fixed drug eruption typically presents as an edematous
plaque on the skin that appears quickly after exposure to the
triggering drug. Given time, the inflammation within a fixed
drug eruption lesion subsides leaving only postinflammatory
hyperpigmentation. Upon readministration of the offending
drug, new fixed drug eruption lesions develop elsewhere on
the skin and the older ‘‘resting’’ lesions characteristically again
become inflamed. Presumably, drug-specific CD8 cytotoxic
T cells that express certain activation markers are thought to be
responsible for the LTR/IFD pattern of epidermal damage seen
in a fixed drug eruption. Curiously, CD8-positive cytotoxic
T cells have been shown to persist as a stable population in
resting fixed drug eruption lesions between periods of
clinically evident inflammation (data reviewed by Shiohara
and Mizukawa, 2005). These ‘‘residual’’ CD8 T cells are
intimately associated with activated macrophages/dendritic
cells within ‘‘resting’’ fixed drug eruption lesions. A similar
association of activated CD8 T cells and activating antigen-
presenting cells (APCs) has been observed in the healed skin
following herpes simplex virus infection. It has been suggested
that these persisting activated CD8 T cells and APCs are a
result of persistent, low-level viral antigen expression. Shiohara
et al. have suggested that CD8 T cells that remain enriched in
resting fixed drug eruption lesions could have originally
evolved to prevent reactivation of viruses such as herpes
simplex virus from latency. Accidental reactivation of this
cytotoxic T-cell population by cross-reactive drug antigens
could result in a localized LTR/IFD injury pattern seen in the
fixed drug eruption (Shiohara and Mizukawa, 2005). Other
workers including Lodi et al. (2005) who have been focused
predominately on the etiopathogenesis of oral lichen planus
have presented similar unifying models. Figure 5 presents a
compilation of these and related thoughts.
At stage no. 1 of Figure 5, APCs (epidermal Langerhans
cells, dermal dendritic cells) and basal keratinocytes are
‘‘activated’’ by viral infection, bacterial products, mechanical
trauma, systemic drugs, contact sensitivity, UV light, or other
unidentified agents. TLR-7 and TLR-9 signaling by plasma-
cytoid dendritic cells recruited into this early milieu of innate
immune activation could amplify the activating effects of
such stimuli via IFN-a production. Plasmacytoid dendritic
cells expressing Fc receptors could also be further activated
in this setting by immune complexes containing foreign (viral)
or self (U1RNA, hYRNA) (Kelly et al., 2006; Kelly-Scumpia
et al., 2007).
During stage no. 2a, activated APCs and keratinocytes
secrete cytokines and chemokines that attract lymphocytes
into the developing lichen planus lesion. Specific chemokine
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and chemokine receptor pairs that have recently been
implicated as playing a role in the LTR/IFD (for example,
CXCL-10/CXCR3) will be discussed by others in these
proceedings. Activated dendritic APCs present antigen
associated with MHC class II to CD4 T cells. CD40 and
CD80 coexpression and IL-12 secretion by MHC class II
dendritic APCs promote a Th-1 CD4 T cell response. During
stage no. 2b, activated basal keratinocytes present antigen
associated with MHC class I to CD8 T cells.
At stage no. 3a, Th-1 CD4 T cells secrete IL-2 and INF-g,
which bind to their respective receptors on CD8 cytotoxic
T cells (no. 3b). It is possible but not yet confirmed that the
recently described Th-17 cell might play a role at this stage.
Products released from activated mast cells might facilitate
T cells breaching the epidermal basement membrane to enter
the epidermis.
CXCR3-expressing CD8 cytotoxic T cells are recruited
from the circulation into the skin by locally elaborated
chemokines such as CXCL-10. Activated antigen-specific
CD8 cytotoxic T cells express FasL, secrete granzymes/
perforin and/or tumor necrosis factor (TNF)-a (stage no. 4)
that trigger basal cell keratinocyte apoptosis (no. 5). As
discussed previously, there is evidence that basal keratino-
cytes in the LTR/IFD undergo necrosis as well as apoptosis.
It is also possible that injured keratinocytes in this setting
express heat-shock/stress-response proteins in a variant
fashion (Chaiyarit et al., 1999; Bayramgurler et al., 2004).
Such proteins might also be the targets of an autoimmune
response.
It has been suggested that two antigens might be required
for the full development of a LTR/IFD such as lichen planus
(Lodi et al., 2005). As an example, antigen no. 1 might be an
MHC class II-restricted, virus-derived polypeptide that is
processed through endosomal compartments within dendritic
cells. Presentation of this processed antigen by myeloid
dendritic cells to CD4 Th1 cells within the milieu of dendritic
cell derived to proinflammatory cytokines (for example,
TNF-a, IL-1, IL-12) would result in the generation of IL-2
and IFN-g. These latter two cytokines working in concert with
locally derived, IFN-a-induced CXCL9–CXCL11 might result
in the recruitment and activation of CXCR3(þ ) cytotoxic
CD8 T cells. These cytotoxic effector T cells would then
be further activated by MHC class I-restricted, cytoplasm-
processed antigen no. 2 being presented by activated
basaloid keratinocytes. Antigen no. 2 could be a self-antigen
such as a heat shock protein induced on basaloid keratino-
cytes via innate immune response activation (stage no. 5).
Cytotoxic and pro-apoptotic mediators/stimuli expressed by
fully activated cytotoxic CD8 T cells (that is, granzyme,
perforin, fas ligand) could then mediate the basal cell layer
apoptosis and necrosis that is typical of lichen planus.
It is also possible that antigen no. 1 and antigen no. 2 in
Figure 5 could represent the same molecule that gains access
to both the endosomal and cytosolic of antigen-presentation
pathways via mechanism of crossed antigen presentation
(Lodi et al., 2005). An example might be a chemical hapten.
Some LTR/IFD disorders such as a subacute cutaneous LE
are associated with circulating Ro/SS-A and La/SS-B auto-
antibodies. Interestingly, Ro/SS-A and La/SS-B antigens have
been shown to appear in membrane blebs of keratinocytes
undergoing UV light-induced apoptotsis (LeFeber et al.,
1984; Casciola-Rosen et al., 1994) (stage no. 5). It has been
proposed that a component of basal keratinocyte injury
occurring in subacute cutaneous LE lesions might result from
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antibody-dependent cell-mediated cytotoxicity when effector
cells recognize via their Fc receptors the Fc fragments of Ro/
SS-A and La/SS-B autoantibody bound to their antigens on the
surface of apoptotic keratinocytes (Bennion and Norris 1997;
Furukawa et al., 1999). Fc receptor expressing monocytes,
dendritic cells, and NK cells would more likely serve as such
effector cells in this setting compared to T cells, as T cells are
relatively inefficient in expressing Fc receptors. Alternatively,
Ro/SS-A and La/SS-B antibodies bound to their respective
antigens on the surface of UV light-induced apoptotic
keratinocytes might interfere with the physiological nonin-
flammatory clearance of such keratinocytes by phagocytes.
Clancy et al. (2006), who study congenital heart block in the
context of neonatal LE, have reported that the presence of
maternal Ro/SS-A and La/SS-B antibodies inhibits the
phagocytosis of apoptotic cardiocytes by surrounding resi-
dent cardiocytes.
Deficient inflammation-dampening mechanisms in LTR/IFD?
As Shiohara has pointed out, many LTR/IFD disorders
including lichen planus display a finite lifespan characterized
by spontaneous resolution (Shiohara and Mizukawa, 2005).
This implies that the LTR/IFD reaction pattern might represent
a physiological mechanism for maintaining the integrity of
epidermal basal cells that has gone awry. Genetic poly-
morphism of pro-inflammatory and/or anti-inflammatory
components of such a protective mechanism could be at
play. Polymorphism of pro-inflammatory pathways including
cytokines (fir example, INF-g, TNF-a, IL-18) have been
reported in lichen planus. In addition, polymorphism of a
number of anti-inflammatory pathways is possible in lichen
planus. For example, variant expression of the TGF-b/Smad
pathway has been reported in lichen planus (Karatsaidis
et al., 2003). In addition, low rates of apoptosis of
lymphocytes infiltrating lichen planus lesions have been
observed (Bascones-Ilundain et al., 2006). Also, variant
expression of cytokine inhibitors such as soluble TNF-a
receptors and IL-1 receptors might also play a role. As
discussed previously, preliminary studies have found no
quantitative abnormalities in FOXP3(þ ) T regulatory cells in
lichen planus.
A number of less well-known molecules have been
implicated in downregulating the inflammation of lichen
planus. Examples include soluble inhibitors of cytokines
(soluble TNF receptor, soluble IL-1 receptor), resolvins, and
protectins (Ariel and Serhan, 2007; Schwab et al., 2007). In
addition, indoleamine 2,3-dioxygenase, which degrades
tryptophan and suppresses T-cell proliferation, is induced
by IFNs and other inflammatory cytokines (Scheler et al.,
2007). Variant expression of this molecule could also
play a role in faulty downregulation of INF-a-mediated
inflammatory pathways. The entire field of physiological
downregulation of acute and chronic inflammation deserves
more attention in the context of lichen planus and other LTR/
IFD disorders (Wells et al., 2005; Lawrence and Gilroy 2007).
Any etiopathogenetic model of lichen planus and other
LTR/IFD disorders needs to account for several consistent
clinical features of this group of diseases. Nonspecific skin
trauma will precipitate skin disease activity in noninvolved
skin in some LTR/IFD disorders such as lichen planus and
cutaneous LE (that is, the Ko¨ebner or isormorphic response).
In addition, induction or exacerbation by UV light is a
characteristic of some LTR/IFD disorders such as cutaneous
LE and cutaneous dermatomyositis.
TREATMENT
Treatment of this diverse group of cutaneous disorders is
guided by the degree of symptomatology, disability, and
associated systemic illness. Banal, self-limited dermatoses
such as lichen nitidus and lichen striatus are treated with
topical immunomodulatories (for example, corticosteroids,
calcineurin inhibitors) until they spontaneously remit. Photo-
avoidance and broad-spectrum sunscreen use can be of
benefit to UV light-induced/exacerbated LTR/IFD disorder
such as cutaneous LE and cutaneous dermatomyositis.
Severely symptomatic, potentially disfiguring/disabling
LTR/IFD disorders can be more difficult to treat. Intractable
lichen planus rubra and erosive lichen planus of the genitalia
can require systemic immunosuppressive/immunomodula-
tory therapy (for example, corticosteroids, cyclosporine,
mycophenolate mofetil), with the attendant risks for signifi-
cant side effects. Similar systemic treatment approaches are
required for fulminant, life-threatening LTR/IFD disorders
such as erythema multiforme major (Stevens–Johnson syn-
drome) and toxic epidermal necrolysis.
LTR/IFD dermatoses that are associated with potentially
life-threatening systemic diseases are treated empirically in a
graded fashion depending upon the severity of the cutaneous
and systemic manifestations. Limited forms of cutaneous LE,
cutaneous dermatomyositis, and graft-versus-host skin dis-
ease can be treated with topical immunomodulatory therapy
and systemic nonimmunosupressive anti-inflammatory
agents such as the aminoquinoline antimalarials (hydroxy-
chloroquine, chloroquine, quinacrine) and dapsone. When
the cutaneous manifestations of these disorders are severe or
are associated with significant systemic disease activity/
injury, systemic immunosuppressive/immunomodulatory
therapy is required (corticosteroids, methotrexate, azathio-
prine, mycophenolate). Because of the rarity of many of the
LTR skin disorders, virtually all of the above-noted treatment
modalities are carried out on an ‘‘off-label’’ non-FDA-
indicated basis.
In a reverse engineering approach, determining how empi-
rically derived therapeutic agents actually work in controlling
LTR/IFD inflammation could provide additional insight into
the immunological mechanisms of these disorders. As an
example, aminoquinoline antimalarial drugs such as hydro-
xychloroquine, chloroquine, and quinacrine are especially
useful in controlling lupus-specific skin disease inflammation.
Although antimalarials are thought to have numerous
inhibitory effects on the inflammatory response, they are
now known to downregulate Toll-like receptor expression
due to their ability to alkalinize intracellular endosomal
compartments (Kalia and Dutz, 2007). As has been men-
tioned elsewhere, Toll-like receptor signaling within plasma-
cytoid dendritic cells resulting in IFN-a production is thought
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to play a key role in the pathogenesis of LE-specific skin
disease and other LTR disorders. Why antimalarial drugs are
not as clinically effective in lichen planus and cutaneous
dermatomyositis as they are in cutaneous LE is not clear.
Lymphocyte function assoc. antigen (LFA-1) is expressed
by T cells in the inflammatory infiltrate of all LTR/IFD skin
disorders. LFA-1–intercellular adhesion molecule (ICAM-1)
interaction facilitates T cells gaining access to the extra-
vascular compartment of the skin and also facilitates
T cell stimulation by APCs within the skin. Recent anecdotal
observations have suggested that blocking the LFA-1–ICAM-1
costimulatory pathway might be of benefit to a number of
different LTR/IFD skin disorders. One such recombinant
biological drug that interferes with this costimulatory path-
way, efalizumab (Raptiva), has been reported anecdotally to
be of clinical benefit in multiple LTR/IFD (for example, lichen
planus (Cheng and Mann, 2006; Bohm and Luger, 2007),
cutaneous LE (Clayton et al., 2006; Usmani and Goodfield,
2007), cutaneous dermatomyositis (Huber et al., 2006)).
Systematic studies are needed to confirm the preliminary
clinical observations.
There are several small-molecule approaches on the
horizon that might prove to be of clinical benefit in LTR/
IFD disorders. As an example, several classes of small-
molecule inhibitors of the CXCR3 receptor are currently
being developed (for example, imidazole derivatives) (Du
et al., 2007; Knight et al., 2007; Li et al., 2007; Mohan and
Issekutz 2007; Turner et al., 2007; Suzaki et al., 2008). These
inhibitors are currently being examined in other T-cell
mediated autoimmune diseases such as rheumatoid arthritis
and asthma and perhaps might play a role therapeutically in
LTR/IFD disorders in the future.
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